NTM/MAC/MAI: We must advocate for ourselves

Posted by boomerexpert @boomerexpert, Aug 16, 2016

Throughout the US & its territories, a total of 8580 people are infected with Zika, a virus that is easily prevented and does not harm adults - it can cause birth defects in unborn children of infected people, but that can be prevented. The US is spending hundreds of millions of dollars to search for a vaccine.

In contrast, 1 of every 100,000 people (not including people with HIV) in the US are diagnosed with some form of NTM, most prevalent is MAC/MAI, and that figure is increasing. Under "NTM Facts, A Growing Problem" (https://www.ntmfacts.com/prevalence), here's a few alarming statistics:
"Currently, there are an estimated 86,000 cases of NTM lung infections in the US, and that number continues to grow more than 8% in prevalence every year. (with no requirement to report NTM infections as there is for TB, most researchers believe the number is far higher).
With the rise of NTM infections, data has shown that NTM is now more prevalent than TB in the US...it has been found that incidences of NTM are increasing while TB is decreasing around the US. ...The rates of NTM infection are increasing in patients aged 65 and over, a population
that is expected to double by the year 2030."

The infection went from one considered as opportunistic (effects mostly those who are very compromised, like the HIV infected) to one that has now invaded the general population.

Yet, by all research and medical standards, treatment with first 2, and now 3 (and in some cases 4) extremely powerful antibiotics is grueling (side-effects similar to those experienced with chemotherapy) thus difficult (for some impossible) to sustain as it must be taken 3X/day for at least 1 year, thus its effectiveness as a cure in many patients is spotty; for an increasing number it can only manage the infection, causing them to be on strong antibiotics for the rest of their lives.

In essence, the bug has become more prevalent (and perhaps stronger), and the medical community's response has been minimal research to ID current antibiotics that may work better than others, then increase the number used to treat it rather than find more appropriate treatments designed to kill this particular bacteria. Exacerbating the problem is the medical conundrum that taking these medications orally has a reduced impact on this infection deep in the lungs. Most researchers agree that the best solution is something that can be introduced directly to the lung via aerosol or inhalant.

Over the past 18 years, no significant research beyond that mentioned above has been conducted to find a more effective cure. The only clinical trial conducted over the past 5 years for an inhaled treatment, Amikacin, is generally being tested on those who have already failed traditional treatments, thus not supplanting them.

I believe that patients who endure the impact of this medical vacuum must push for more research, and better treatments, not just more clinically effective, but with far less side-effects. We can start by contacting top research facilities for this condition (U TX, National Jewish, Mayo Clinic, and the NIH, FDA) asking for more research. We can also talk with our physicians about better treatments, asking them to push for more research. Finally, we can continue to search for, and share, information on clinical trials for new NTM treatments, and our ideas for treatments that could work.

If these facilities continue to hear from a great number of people suffering from this insidious infection, it may have the "squeaky wheel" effect. Most assuredly if we remain silent, willing to trudge along with the existing treatments without asking for something better, we are likely to get nothing better.

I believe patients themselves can have a great impact on improving research. But...only if they hear from us.

Thoughts? Ideas?

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

@unicorn

AIT Therapeutics Announces $9.82 Million Private Placement

NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that it has completed a private placement with a select group of investors, which, assuming the exercise of the Tranche A portion of the warrants (as described below) sold in the private placement, will result in gross proceeds to the Company of approximately $9.82 million, before deducting placement agent fees and offering expenses. The private placement consists of warrants to purchase shares of the Company’s common stock. Each warrant is comprised of (i) 2,299,802 Tranche A warrants to purchase one share of common stock at an exercise price of $4.25 per share, exercisable within three days from warrant issuance, and (ii) an equal number of Tranche B warrants to purchase one share of common stock at an exercise price of $4.25 per share, exercisable within three years from warrant issuance. The Company has also agreed to provide the investors customary resale registration rights with respect to the shares of common stock issuable upon exercise of the warrants.

AIT Therapeutics expects to use the proceeds from the offering primarily to support the Company’s ongoing operations related to its three inhaled Nitric Oxide (NO) programs:

Persistent Pulmonary Hypertension of the Newborn (PPHN)
• AIT anticipates a 510k regulatory submission in the United States (US) around year-end 2018
• Select regulatory filings outside the US are planned to begin in 2019

Bronchiolitis (BRO)
• Data from a pilot study were published in 2017 in the Pediatric Pulmonology Journal
• A 94 patient study is ongoing in Israel with top-line data expected to be reported early in the second quarter of 2018
• A US pivotal study is expected to start in the fourth quarter of 2018 and complete in the second quarter of 2019 with a US regulatory filing to follow shortly thereafter
• Regulatory filings outside the US are planned to begin in 2020
Nontuberculous Mycobacteria (NTM) Abscessus
• AIT recently announced preliminary results from a pilot study and will present the full dataset at the American Thoracic Society Meeting, to be held in San Diego from May 18 to 23, 2018
• AIT anticipates meeting with FDA during the second quarter of 2018 to discuss a pivotal trial design
• AIT anticipates the completion of treatment of one cystic fibrosis patient suffering from NTM abscessus around the end of the first quarter 2018. The treatment will be administered at the National Heart, Lung, and Blood Institute (NHLBI) with our commercial scale generator based NO delivery system
Laidlaw & Co. (UK) Ltd. acted as lead placement agent for the transaction and Brookline Capital, a division of CIM Securities, acted as co-placement agent.

The securities to be sold in this private placement have not been registered under the Securities Act

Jump to this post

Here's hoping a)it goes through and b)they follow through!

REPLY

@unicorn and @boomerexpert.....well no doubt The website bronchiectasis will report on the ATSociety results after May....
Is one client with cystic fibrosis AND NTM abscesses enough to draw conclusions on? Tdrell

REPLY

@boomerexpert....but I guess one is better than none.tdrell

REPLY
@tdrell

@unicorn and @boomerexpert.....well no doubt The website bronchiectasis will report on the ATSociety results after May....
Is one client with cystic fibrosis AND NTM abscesses enough to draw conclusions on? Tdrell

Jump to this post

They had more than one I believe, 9 in phase 2, not sure how many in phase 1, all positive results. And Israel has more people also. They said I could be in next trial!

REPLY

Unfortunately statistically one is the same as none for research purposes...

REPLY
@heathert

I have emailed the Nat Jewish Hosp lab team and FDA with an idea of treating MAC by inhaling a healthy lung bacteria that cannot co-exist with MAC(like the pink scum bacteria in our bathrooms that does not coexist with MAC), and can eradicate it from our lungs, or stop it from re colonising. It makes sence that we are killing off healthy bacteria in our homes with chemicals and hotter hot water temperatures, but the MAC can survive these chemicals and thrive without the other bacteria killing it off, then we only inhale live MAC not the other healthy types that do not cause lung disease. Who knows what they will think about my idea but if we dont try we wont know, so worth a go and maby it will jog their great scientific brains in some other helpful way ,if this idea is not possible.

We may not be medical scientists, but believe in ourselves and between us we can help!

Jump to this post

@heathert...did you ever hear back from NJH or FDA? Tdrell

REPLY
@heathert

I have emailed the Nat Jewish Hosp lab team and FDA with an idea of treating MAC by inhaling a healthy lung bacteria that cannot co-exist with MAC(like the pink scum bacteria in our bathrooms that does not coexist with MAC), and can eradicate it from our lungs, or stop it from re colonising. It makes sence that we are killing off healthy bacteria in our homes with chemicals and hotter hot water temperatures, but the MAC can survive these chemicals and thrive without the other bacteria killing it off, then we only inhale live MAC not the other healthy types that do not cause lung disease. Who knows what they will think about my idea but if we dont try we wont know, so worth a go and maby it will jog their great scientific brains in some other helpful way ,if this idea is not possible.

We may not be medical scientists, but believe in ourselves and between us we can help!

Jump to this post

@tdrell Just the normal replys like sign up to follow them. Nothing hopeful unfortunatly. 🙁

REPLY
@tdrell

@unicorn and @boomerexpert.....well no doubt The website bronchiectasis will report on the ATSociety results after May....
Is one client with cystic fibrosis AND NTM abscesses enough to draw conclusions on? Tdrell

Jump to this post

I would like to join you in the next trial.

REPLY
@tdrell

@unicorn and @boomerexpert.....well no doubt The website bronchiectasis will report on the ATSociety results after May....
Is one client with cystic fibrosis AND NTM abscesses enough to draw conclusions on? Tdrell

Jump to this post

Jo Ann not up to me, get in touch with AIT . Not sure i am in anyway. one doc said he would get in touch, but that is still no guarantee

REPLY
Please sign in or register to post a reply.